Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PerVax-01
- Development stage
- Preclinical
- Lead developer
- Beijing Xunsheng Biomedical Research
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PerVax-01 is an individualized, personalized therapeutic nucleic acid vaccine being developed by Beijing Xunsheng Biomedical Research (Aeonvital) for the treatment of cervical precancerous lesions and cervical cancer. Administered via intramuscular injection, the vaccine is designed to stimulate patient-specific immune responses against tumor neoantigens. It is currently in the IND-enabling phase of development, with clinical trials anticipated to begin in 2027.
Beyond the preview
Go deeper on PerVax-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PerVax-01.